Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
NCT03571204Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2018
- Primary completion
- Mar 2021
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Participants With Grade 3 or Higher Adverse Events at 29 months. Started Sep 2018; status: terminated.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03571204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571204.